AIPM welcomes Inpharmus, Distributor of Rare Disease Medicines

Moscow, January 27, 2026 — The Association of International Pharmaceutical Manufacturers (AIPM) has announced the integration of Inpharmus as a full member. This decision was reached at the AIPM General Meeting in December 2025. Inpharmus, with a presence in 23 countries, collaborates with over 40 leading biopharmaceutical companies, including Fennek Pharma, Pharming, and Santera Pharmaceuticals. Its focus areas include oncology, hematology, immunology, neurology, and the treatment of rare diseases.

In the final quarter of 2024, Inpharmus expanded its global reach by establishing a Russian branch, Infarmus LLC. This new entity specializes in distributing innovative treatments and ensuring patient access to cutting-edge therapies. The company works closely with charitable foundations and non-profits, supplying both registered and unregistered medications in the Russian Federation. This is particularly crucial for patients requiring expensive, high-tech treatments, including those for rare diseases.